8月8日周五盘前，生物技术公司Natera, Inc.（纳斯达克股票代码：NTRA）股价大涨13.43%，主要受益于公司发布的2025财年第二季度强劲财报。
根据Natera公布的财报，公司2025财年第二季度实现收入5.466亿美元，同比增长32.2%，远超分析师预期的4.7629亿美元。尽管公司仍录得亏损，但每股亏损74美分好于华尔街预期的最大亏损75美分。公司毛利率提升至63.4%，较去年同期的59%有显著改善。受此利好消息推动，多家券商上调了Natera的目标价，其中BTIG将目标价从195美元上调至200美元，摩根大通将目标价从200美元上调至210美元。
展望未来，Natera管理层上调了全年收入指引至20.2亿至21亿美元，并将毛利率指引提高至61%-64%。公司表示将继续推出新产品，扩大Medicare覆盖范围，并加大人工智能技术的应用，以进一步提升运营效率和市场竞争力。尽管市场渗透率仍然较低，但Natera对其在各类肿瘤检测市场的扩张机会持乐观态度，这也增强了投资者对公司长期增长前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.